Spyre Therapeutics, Inc. SYRE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s additional paid-in capital?
- Spyre Therapeutics, Inc. (SYRE) reported additional paid-in capital of $1.71B in Q1 2026.
- How has Spyre Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Spyre Therapeutics, Inc.'s additional paid-in capital increased by 27.5% year-over-year, from $1.34B to $1.71B.
- What is the long-term trend for Spyre Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s additional paid-in capital has grown at a 32.3% compound annual growth rate (CAGR), from $415.82M to $1.69B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.